Brief: Roivant Announces Genevant Sciences’ And Arbutus Biopharma’S $2.25 Billion Global Settlement With Moderna
03/03/2026 21:21
March 3 (Reuters) - Arbutus Biopharma Corp ABUS.O: ROIVANT ANNOUNCES GENEVANT SCIENCES’ AND ARBUTUS BIOPHARMA’S $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA ROIVANT SCIENCES : BOARD APPROVED $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT SCIENCES: UNDER SETTLEMENT, GENEVANT TO GIVE MODERNA NON-EXCLUSIVE LICENSE TO LNP DELIVERY TECHNOLOGY FOR INFECTIOUS DISEASE APPLICATIONS Source text: ID:nGNX8tTKPd Further company coverage: ABUS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arbutus Biopharma
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug
Brief: Arbutus Announces Final Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Brief: Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare